
Medical technology company ResMed continues to expand demand for its sleep apnoea devices, defying predictions growth in weight-loss drugs will undercut its market.
The Sydney-founded, California-domiciled company on Friday AEST reported revenue grew by nine per cent in the quarter ended June 30 to $US1.22 billion ($A1.88 billion), roughly in line with analyst expectations.